FMP
OncoCyte Corporation
OCX
NASDAQ
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
2.08 USD
-0.04 (-1.92%)
Parth Sanghvi
Jan 8, 2025
A shareholder of Berkshire Hathaway, Tulipshare, has submitted a resolution calling for the creation of an independent committee to oversee risks associated with artificial intelligence (AI) across Warren Buffett’s conglomerate. This initiative will be presented at Berkshire's annual meeting on May 3, highlighting concerns about the potential misuse of AI and its implications for privacy, data security, and human rights. Why It Matters Berkshire Hathaway, with its sprawling portfolio of co...
MCAP MediaWire
Aug 5, 2024
IRVINE, Calif., August 5, 2024 — Oncocyte Corp.
MCAP MediaWire
Aug 1, 2024
Conference Call and Webcast on Thursday, August 8, 2024 at 2:00 p.m. PT / 5:00 p.m.
Seeking Alpha
May 15, 2024
OncoCyte Corporation (NASDAQ:OCX ) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Jeff Ramson - Investor Relations Josh Riggs - President and Chief Executive Officer Conference Call Participants Mike Matson - Needham Mason Carrico - Stephens Operator Good afternoon. My name is Briana and I will be your conference operator today.
24/7 Wall Street
Apr 21, 2024
At the end of the previous week, the Oracle of Omaha yet again boosted his stake in a media giant's tracking stocks, even with shares still in retreat.
GlobeNewsWire
Apr 9, 2024
IRVINE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will release its fourth quarter and full year 2023 financial results on Friday, April 12, 2024, prior to the U.S. market open.
Seeking Alpha
Nov 9, 2023
OncoCyte Corporation (NASDAQ:OCX ) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Stephanie Prince - IR, PCG Advisory Josh Riggs - President & CEO Conference Call Participants Mike Matson - Needham Jacob Krahenbuhl - Stephens Vidyun Bais - BTIG Operator Thank you for standing by. My name is Tamika and I will be your conference operator today.
GlobeNewsWire
Nov 3, 2023
Conference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET Conference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET
Seeking Alpha
Aug 10, 2023
OncoCyte Corporation (NASDAQ:OCX ) Q2 2023 Earnings Conference Call August 10, 2023 8:00 AM ET Company Participants Stephanie Prince - PCG Advisory, IR Josh Riggs - President and CEO Conference Call Participants Mike Matson - Needham & Co. Operator Welcome to the OncoCyte Q2 2023 Earnings Call. All participants will be in listen-only mode.
GlobeNewsWire
Apr 27, 2023
IRVINE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it will release its first quarter 2023 financial results on Thursday, May 11, 2023, before U.S. market open.